ClinicalTrials.gg
Not yet recruitingNCT07430267ACE-DOUBLEUpdated Feb 24, 2026

Dilation Optimisation for Uniform Bioprosthetic Leaflet Expansion

An interventional study of 'Double tap' balloon post-dilation in Aortic Stenosis and TAVI(Transcatheter Aortic Valve Implantation), sponsored by The Alfred. Not yet recruiting at 3 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by The Alfred · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Aortic Valve Stenosis with a site in Australia — 10 open to participants now, 15 under way, none of them phase 3. Aortic Valve Stenosis · Australia.

Planned enrollment
17th of 28
250 · median 358
Started
2026
with 1 other
No phase
28 of 35
8 open now
Primary completion
2028-04
later than 11 of 14 live
Registered
34th of 35
by date
Lead sponsor
2 of 35
The Alfred

Among the 35 studies in Aortic Valve Stenosis with a site in Australia, this one is the 17th largest by planned enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2026, is one of 28 with no phase, reaches primary completion later than 11 of the 14 other live ones, and was the 34th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

10 of the 35 studies in Aortic Valve Stenosis with a site in Australia are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Aortic Valve Stenosis with a site in Australia, or all of them as a file.
02

Study summary

The goal of this clinical trial is to discover if routine 'double tap' balloon post-dilation improves valve expansion and clinical outcomes in adults undergoing Transcatheter Aortic Valve Implantation (TAVI) with the SAPIEN balloon-expandable TAVI prosthesis.

The primary hypothesis is that routine 'double tap' balloon post-dilation improves TAVI valve expansion. The secondary hypothesis is that routine 'double tap' balloon post-dilation improves TAVI valve haemodynamic performance.

Participants will be randomised to balloon-expandable TAVI either with or without routine 'double tap' balloon post-dilation.

Read the detailed description

The ACE-DOUBLE trial will be a multicentre, registry nested, block randomized, open label clinical trial comparing routine versus discretionary balloon post-dilation strategies following TAVI using the SAPIEN 3 balloon-expandable THV for severe aortic stenosis (AS).

Patients with severe symptomatic aortic valve disease that are accepted for TAVI using a balloon-expandable THV. Currently, the only balloon-expandable THV in routine clinical practice in Australia are the Sapien 3 Ultra and Sapien 3 Ultra Resilia (Edwards Lifesciences, Irvine CA, USA). Patients will be recruited from three TAVI centres participating in the ACE registry: The Alfred Hospital, Cabrini Hospital and Epworth Hospital are all located in Melbourne, Australia.

Specific sub-groups may benefit more from balloon post-dilation (BPD), and hence exploratory analyses will be performed to examine the effect of BPD on primary endpoints in the following subgroups:

  • Male vs Female
  • Pre-dilation vs no pre-dilation
  • Tricuspid vs bicuspid aortic valve
  • Very severe AS (mean pressure gradient > 50mmHg)
  • Very aortic valve high calcium score (>3000 in males, >1900 in females)
03

Conditions studied

  • Aortic Stenosis
  • TAVI(Transcatheter Aortic Valve Implantation)

Keywords

  • TAVI
  • TAVR
  • Double Tap
  • balloon post-dilation
  • Balloon-expandable TAVI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Severe aortic stenosis undergoing trans-femoral TAVI using the SAPIEN 3 Ultra/RESILIA balloon-expandable transcatheter heart valve.
  • Tricuspid or bicuspid aortic valve stenosis

Exclusion criteria

Exclusion Criteria:

  • Valve-in-valve TAVI for failure of an existing prosthetic surgical or transcatheter valve failure
  • TAVI performed for native valve aortic regurgitation
  • High risk 'hostile' annular anatomy as adjudicated by multidisciplinary Heart Team based on pre-procedure CT anatomy.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
250 participants (estimated)

Study arms

  • No intervention
    Routine deployment

    Participants in the routine deployment arm will have no further post-dilation after satisfactory initial deployment of the balloon-expandable THV

  • Experimental
    Routine double tap

    Participants in the double tap arm will undergo a second inflation of the delivery system balloon at the same filll volume after satisfactory initial deployment of the balloon-expandable THV

    Other: 'Double tap' balloon post-dilation

Interventions

  • Other'Double tap' balloon post-dilation

    Routine second inflation of the valve delivery balloon ('double-tap') BPD following balloon-expandable valve TAVI

06

What researchers measure

Primary outcomes

  1. Fluoroscopic valve expansion

    Percentage (%) final valve expansion measured by fluoroscopy

    Time frame: Day 1 post-procedure

Secondary outcomes

  1. Haemodynamic performance

    Echocardiographic transvalvular mean pressure gradient (mmHg)

    Time frame: Day 1-3 post-procedure

  2. Haemodynamic performance

    Echocardiographic aortic valve area (cmsq)

    Time frame: Day 1-3 post-procedure

  3. Freedom from cardiovascular death or valve reintervention

    Freedom from occurrence of composite of cardiovascular death or valve reintervention

    Time frame: 1 year and 3 years post-procedure

Other outcomes

  1. CT sub-study: final valve expansion measured by non-contrast computed tomography

    CT sub-study: final valve expansion (%) measured by non-contrast computed tomography

    Time frame: 30-90 days post-procedure

  2. New permanent pacemaker implantation

    New permanent pacemaker implantation

    Time frame: 30 days post-procedure

  3. Stroke

    Confirmed stroke

    Time frame: 30 days post-procedure

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No — Individual participant data cannot be released without specific approval from the HREC committee.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Apr 2028, 24 months later.

Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 24 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Feb 24, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Apr 1, 2028
CompletionEst.
Apr 1, 2029
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07430267
Lead sponsor
The Alfred
Responsible party
Nalin Dayawansa (Associate Investigator, The Alfred) — Principal investigator
First posted
Feb 24, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Apr 1, 2028 (estimated)
Completion
Apr 1, 2029 (estimated)
Last update
Feb 24, 2026

Study contacts

Nalin H Dayawansa, MBBS
Contact
na.dayawansa@alfred.org.au
+61390765784

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion